Open AccessAntidiabetic Activity of Terfezia Claveryi; An In Vitro and In Vivo Study
Author(s) -
Anas AlAhmed,
Hany Ezzat Khalil
Publication year - 2019
Publication title -
biomedical and pharmacology journal/biomedical and pharmacology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.191
H-Index - 18
eISSN - 2456-2610
pISSN - 0974-6242
DOI - 10.13005/bpj/1680
Subject(s) - acarbose , in vivo , glibenclamide , ic50 , chemistry , in vitro , enzyme , amylase , biochemistry , pharmacology , traditional medicine , biology , medicine , diabetes mellitus , endocrinology , microbiology and biotechnology
The main objective of current study was to investigate the in vitro and in vivo antidiabetic activity of Terfezia claveryi methanol extract. In vitro antidiabetic assays such as inhibition of α-amylase enzyme and non-enzymatic glycosylation of hemoglobin were carried out. The results of α- amylase inhibition assay revealed that the inhibitory activity (IC50) of Terfezia claveryi methanol extract (38.7µg/ml) is stronger when compared with positive control (Acarbose IC50 value of 45.3 µg/ml). The inhibition of glycosylation of hemoglobin of Terfezia claveryi methanol extract showed almost the same IC50 (33.1µg/ml) when compared the positive control, alpha-tocopherol (35.4µg/ml). In vivo antidiabetic study revealed that Terfezia claveryi methanol extract possessed good activity at a dose of 200 mg/kg through reducing the fasting plasma glucose level (122.1±3.0 mg/dl) when compared with positive control (Glibenclamide of 79.4±1.4 mg/dl) (p < 0.001). The results from this study indicated that Terfezia claveryi methanol extract exhibited considerable in vitro and in vivo antidiabetic activities. These possible activities could be useful to consider Terfezia claveryi as therapeutic antidiabetic candidate.